Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.

OBJECTIVE Insulin regulates the GH-IGF1 axis. Insulin analogs differ from human insulin in receptor affinity and possibly liver accessibility. Therefore, we compared the GH-IGF1 axis response with human NPH insulin, insulin detemir, and insulin glargine in patients with type 1 diabetes (T1D). METHODS A total of 17 patients (seven were women) with T1D (age of 42 (24-63) years (mean and range), BMI of 24.7 (19.5-28.3) kg/m(2), HbA1c of 7.2 (6.3-8.0) % (55 (45-64) mmol/mol), T1D duration of 26 (8-45) years) were studied using a randomized, three-period crossover design. Patients received s.c. injections of equal, individual doses of NPH, detemir, and glargine at 1800 h. Plasma glucose, serum total IGF1, bioactive IGF, IGF-binding protein (IGFBPs), and GH were measured hourly for 14 h post-injection. RESULTS When compared with the area under the curve (AUC) following NPH and glargine, detemir resulted in the lowest 6-14 h AUC (mean and range) of IGFBP1 (1518 (1280-1800)) vs 1621 (1367-1922) vs 1020 (860-1210) μg/l×h) and GH (17.1 (14.1-20.6) vs 15.4 (12.7-18.6) vs 10.2 (8.5-12.3) μg/l×h), but in the highest AUC of bioactive IGF (3.8 (3.5-4.2) vs 3.7 (3.4-4.0) vs 4.4 (4.1-4.8) μg/l×h) (all P<0.01). These differences were unrelated to plasma glucose. By contrast, profiles of total IGF1, IGFBP2, and IGFBP3 were comparable. CONCLUSIONS Independent of plasma glucose, a single dose of detemir caused larger suppression in serum IGFBP1 than NPH and glargine, whereas bioactive IGF was higher, thereby explaining the lower GH levels. Thus, detemir appears to be more liver specific than NPH insulin and glargine.

[1]  J. Frystyk,et al.  Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: a randomized open-label crossover study , 2013, BMC Nephrology.

[2]  J. Frystyk,et al.  Quantification of the GH/IGF-axis components: lessons from human studies. , 2012, Domestic animal endocrinology.

[3]  J. DeVries,et al.  Insulin detemir versus insulin glargine for type 2 diabetes mellitus. , 2011, The Cochrane database of systematic reviews.

[4]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[5]  J. Rungby,et al.  Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24‐h euglycaemic clamp studies in healthy humans , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[6]  A. Pfeiffer,et al.  The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. , 2009, The Journal of clinical endocrinology and metabolism.

[7]  D. Russell-Jones,et al.  Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes , 2009, Diabetologia.

[8]  A. Kotronen,et al.  Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. , 2008, The Journal of clinical endocrinology and metabolism.

[9]  G. Bolli,et al.  Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. , 2008, Diabetes technology & therapeutics.

[10]  D. Clemmons,et al.  Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer , 2007, Nature Reviews Drug Discovery.

[11]  T. Pieber,et al.  Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies , 2007, Diabetes, obesity & metabolism.

[12]  A. Caumo,et al.  Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. , 2006, European journal of endocrinology.

[13]  J. Frystyk.  The Growth Hormone Hypothesis - 2005 Revision , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[14]  F. Shojaee-Moradie,et al.  Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp , 2005, Diabetologia.

[15]  J. Frystyk,et al.  Residual β-Cell Function More than Glycemic Control Determines Abnormalities of the Insulin-Like Growth Factor System in Type 1 Diabetes , 2004 .

[16]  A. Flyvbjerg,et al.  The physiological and pathophysiological roles of the GH/IGF-axis in the kidney: lessons from experimental rodent models. , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[17]  L. Heinemann,et al.  Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. , 2004, Diabetes.

[18]  H. Orskov,et al.  A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. , 2003, American journal of physiology. Endocrinology and metabolism.

[19]  P. Sönksen,et al.  The role of the growth hormone–insulin‐like growth factor axis in glucose homeostasis , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[20]  H. Arnqvist,et al.  Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type 1 diabetes. , 2000, European journal of endocrinology.

[21]  R. Baxter.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. , 2000, American journal of physiology. Endocrinology and metabolism.

[22]  L. Heinemann,et al.  Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304 , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[23]  M. Tauber,et al.  Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM , 1996, Diabetologia.

[24]  M. Tauber,et al.  Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. , 1996, Diabetes & metabolism.

[25]  U. Ribel,et al.  Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs , 1996, Diabetologia.

[26]  K. Hall,et al.  Regulation of insulin-like growth factor binding protein-1 (IGFBP-1) in insulin-dependent diabetes mellitus , 1994, Acta Diabetologica.

[27]  J. Wahren,et al.  Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. , 1994, The Journal of clinical endocrinology and metabolism.

[28]  H. Orskov,et al.  Free rather than total circulating insulin-like growth factor-I determines the feedback on growth hormone release in normal subjects. , 2005, The Journal of clinical endocrinology and metabolism.

[29]  J. Frystyk,et al.  Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. , 2003, The Journal of clinical endocrinology and metabolism.

[30]  K. Højlund,et al.  Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. , 2002, The Journal of clinical endocrinology and metabolism.

[31]  C. Lang,et al.  Alterations in the Growth Hormone-Insulin-Like Growth Factor Axis in Insulin Dependent Diabetes Mellitus , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.